Jasper Therapeutics presents preclinical data on anti-CD117 antibody
Feb. 26, 2024
Jasper Therapeutics Inc. has presented data at the AAAAI 2024 conference regarding its CD117-targeting antibody briquilimab and its potential use in allergy and CD117-triggered anaphylactic reactions.